These deleterious effects limit the patient populations that can benefit from EPO‐based ESAs, and therefore, an ESA that only activates the EPOR homodimer would be highly desirable as an alternative to pleiotropic EPO for the treatment of anemia. Here, EPOR is linked to anemia.